Rafael price to sales ratio RFL

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 69.5×
8-year median: 63.2×
Against its 8-year history: 64th; percentile: 0 is its lowest day, 100 its highest
8-year range: 8.8× to 199×
Peer median: 1.4×

Rafael's price to sales ratio is 69.5× as of Oct 23, 2026.

That is above its 8-year median of 63.2×, close to the middle of its last 8 years.

Over that time it ranged from 8.8× in May 2022 to 199× in Aug 2021.

The median for 9 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	69.5×	54.6×	167×
2025	60.4×	49.0×	102×
2024	56.3×	56.3×	168×
2023	162×	155×	162×
2022	11.6×	8.8×	26.1×
2021	26.8×	26.8×	199×
2020	77.7×	31.5×	81.3×
2019	57.3×	24.3×	84.4×
2018	23.7×	22.7×	25.8×

Against its peers

Companies in Drug Manufacturers - General nearest Rafael's size, closest first, today.

Company	Price to sales ratio
RFLRafael	69.5×
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ATNMActinium Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Rafael

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.